Stay updated with breaking news from Erics langer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply. From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns. 1 The survey, now in its 18 th year, includes 147 end users’ responses and also provides input from 101 suppliers/vendors worldwide. This year, we find that the industry continues to demand innovative solutions from its suppliers in key areas, but these can often be slow to develop. ....
Looking Back And Moving Forward In The Fight Against SARS-CoV-2 By Eric S. Langer, Managing Partner, BioPlan Associates, Inc., Christopher Murphy, Vice President/General Manager, Viral Vector/Pharma Services, Thermo Fisher Scientific, Brandon Pence, Vice President/General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific, Chris Williams, Vice President/General Manager, Single-Use Technologies, Thermo Fisher Scientific, Kate Torchilin, Vice President/General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific The unprecedented global crisis brought on by SARS-CoV-2 has affected all aspects of life and business. This includes the pharmaceutical industry, where existing trends that were driving incremental changes prior to the pandemic have been accelerated to meet the demand for SARS-CoV-2 vaccine production and delivery. A recent study by BioPlan Associates takes a closer look at the impact of SARS-CoV-2 on bioprocessing, specifically the nea ....
Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19 By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Over the past 17 years we have identified a number of trends that are impacting bioprocessing and biopharmaceuticals manufacturing, the majority of which have promised positive outcomes. With the COVID-19 crisis, many of these ongoing trends have been accelerated. Although it seems we may now be seeing the light at the end of the COVID tunnel, some of the effects of the pandemic on bioprocessing and vaccines manufacturing may result in permanent changes. Major concerns, even pre-pandemic, were continued cost-cutting and often related mergers and acquisitions, but even this trend appears to be slowing. Staffing problems, on the other hand will only get worse, especially with rapid growth in foreign bioprocessing and new cellular and gene therapies-associated capacity. ....
Bioprocessing Year In Review 11 Key Trends Accelerated By COVID-19 pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.